Chief Executive Officer Joe Payne told investors at the Leerink Partners Global Healthcare Conference that the company has advanced its inhaled messenger RNA cystic fibrosis (CF) program through three ...

The Arcturus COVID-19 variant has arrived in the United States and is here to stay, according to experts. While it's unclear whether it will drive a summer surge, some doctors are warning that the ...

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) reported a fourth quarter loss of $1.03 per share and revenue of $7.2 million, as the messenger RNA medicines company ...

Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today ...

Arcturus Therapeutics fell as much as 53% to $40 on Tuesday, extending its losses for a second straight day after Wall Street was disappointed with the medical company's COVID-19 vaccine updates.

Women walk past a coronavirus (COVID-19) themed mural on a street in Mumbai, India, March 28, 2023. REUTERS/Francis Mascarenhas A new coronavirus subvariant, XBB. 1.16, has been designated as a ...

Arcturus' mRNA vaccine will be trying to break into a crowded market if it gets approved. Moderna was in the right place at the right time, and Arcturus isn't. Yet, Arcturus doesn't need to sell many ...